# US 2015/0147404 A1 · Ledgf peptides and formulations thereof for treatment of degenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147404 A1
- Document ID: US20150147404A1
- Status: Published application
- Kind: A1
- Application number: 14/402,426
- Filed: 2013-05-21
- Published: 2015-05-28
- Earliest claimed: 2012-05-21
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, a body corporate
- Inventors: Uday B. Kompella; Rinku Baid; Arun K. Upadhyay; Sarath Yandrapu
- Web page: https://patentgrep.com/patent/US20150147404A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61K 38/18: Growth factors; Growth regulators
- A61K 47/52: the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 39/02: Antidotes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

LEDGF peptides with anti-protein aggregation activity and methods of use are provided. The LEDGF peptides disclosed herein demonstrate an ability to treat degenerative diseases and diseases with various cellular stresses including oxidative stress and protein-aggregation stress. In addition, extended release formulations, including formulations suitable for ophthalmic administration are provided.

## Claims

### Claim 1

A peptide comprising an amino acid sequence of lens epithelium derived growth factor (LEDGF), wherein the peptide comprises a LEDGF N-terminal stress related binding domain.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide further comprises a TAT binding domain.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the peptide has a molecular weight of approximately 40 kDa.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein the peptide has an amino acid sequence of SEQ ID NO: 2., or an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 2.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

A composition comprising the peptide of claim 1.

### Claim 8 (depends on 7)

The composition of claim 7, further comprising a pharmaceutical carrier, diluent, excipient or combination thereof.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the peptide is bound to or associated with a colloidal metal nanoparticle.

### Claim at position 9

10-12. (canceled)

### Claim 13 (depends on 7)

The composition of claim 7, wherein the peptide is bound to, or encapsulated in, an inner particle, and wherein the inner particle is loaded in a porous outer particle.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the inner particle is made from a particle material that does not expand in supercritical carbon dioxide.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the inner particle material is a polymeric material.

### Claim at position 13

16-17. (canceled)

### Claim 18 (depends on 13)

The composition of claim 13, wherein the outer particles are made from a particle material that expands in supercritical carbon dioxide.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the outer particle is a polymeric material.

### Claim at position 16

20-21. (canceled)

### Claim 22 (depends on 7)

A method of treating a protein aggregation-mediated disease comprising administering to a patient in need thereof a composition according to claim 7.

### Claim 23 (depends on 22)

The method of claim 22, wherein the aggregation-mediated disease is an ocular disease or a neurodegenerative disease.

### Claim 24 (depends on 23)

The method of claim 23, wherein the ocular disease is retinal degeneration disease.

### Claim 25 (depends on 24)

The method of claim 24, wherein the retinal degeneration disease is age related macular degeneration (AMD), or retinitis pigmentosa (RP).

### Claim 26

(canceled)

### Claim 27 (depends on 23)

The method of claim 23, wherein the neurodegenerative disease is Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis, or a prion disease.

### Claim 28 (depends on 7)

A method of reducing protein aggregation in a protein aggregation-mediated disease comprising administering to a patient in need thereof a composition according to claim 7.

### Claim 29 (depends on 28)

The method of claim 28, wherein protein aggregation is caused by endoplasmic reticulum stress, oxidative stress, or both.

### Claim 30 (depends on 28)

The method of claim 28, wherein the patient has retinal degeneration disease or a neurogenerative disease.

### Claim at position 26

31-33. (canceled)
